Lenire Marks Historic Inclusion in American ENT Guidelines for Tinnitus Treatment

Lenire Included in U.S. ENT Clinical Practice Guidelines

In a significant milestone for the treatment of tinnitus, the American Academy of Otolaryngology—Head and Neck Surgery Foundation (AAO-HNSF) has integrated Lenire, a bimodal neuromodulation device developed by Neuromod Devices, into its clinical practice guidelines. This decision marks the first addition of a new treatment option for tinnitus since the guidelines were established in 2014.

Lenire stands out as the only FDA-approved device utilizing bimodal neuromodulation, combining auditory stimulation with a mild electrical stimulus applied to the tongue's surface. This innovative treatment offers hope to millions of Americans suffering from the persistent ringing in their ears known as tinnitus.

A New Standard of Care

The decision by AAO-HNSF underscores the emerging understanding of bimodal neuromodulation as a standard treatment for tinnitus. With Lenire now included in the recommendations, over 12,000 ENT specialists can confidently recommend this therapy to patients. This is particularly significant given the high prevalence of tinnitus in the U.S., affecting approximately 50 million adults.

"This is a historic milestone for Neuromod, our technology, and the broader field of tinnitus treatment," said Dr. Ross O’Neill, founder of Neuromod. He emphasized that the inclusion of Lenire in the AAO-HNSF guidelines provides ENT doctors with a safe and effective treatment option that can genuinely assist their patients.

Evidence-Based Approval

The AAO-HNSF's endorsement of Lenire is supported by robust clinical evidence. Several large-scale clinical trials have demonstrated Lenire's efficacy in alleviating tinnitus symptoms. The pivotal trial, referred to as TENT-A3, formed the basis of Lenire's FDA approval in March 2023. This research has been published in high-impact journals, further solidifying the device's credibility within the medical community.

To date, Lenire has benefited tens of thousands of American patients, and the company is committed to expanding the body of evidence supporting its use. Encouragingly, independent evaluations have shown that a clinically significant percentage of users experienced relief from their tinnitus following treatment with Lenire. For instance, one peer-reviewed study reported a notable improvement for 91.5% of patients, while another indicated that 81.8% of those with bothersome tinnitus found significant relief.

Enhancing Access and Outcomes

In addition to FDA approval, Lenire is available through qualified healthcare professionals in the U.S., Canada, Europe, and Australia. It has also become a treatment option for veterans through the U.S. Department of Veterans Affairs. Neuromod Devices is dedicated to enhancing access to this innovative therapy, ensuring that those struggling with tinnitus can receive effective treatment.

Professor Hubert Lim, Neuromod's Chief Scientific Officer, noted that the guideline's inclusion of bimodal neuromodulation strengthens the already substantial clinical evidence backing Lenire. Looking ahead, he expressed Neuromod's commitment to continuing research that can refine and improve the efficacy of Lenire for tinnitus patients worldwide.

This milestone represents not just a victory for Neuromod Devices but also for millions of Americans battling tinnitus, reaffirming the importance of evidence-based, accessible care in the landscape of hearing health. As Lenire gains further traction within the clinical community, it is poised to become an essential choice for those seeking relief from this challenging condition.

For more information about Lenire and its clinical applications, visit Neuromod.

Conclusion

Lenire's introduction into U.S. ENT guidelines marks a transformative shift in the treatment landscape for tinnitus. By emphasizing scientifically validated interventions and providing new pathways for patients seeking relief, this advancement highlights the ongoing evolution of tinnitus care, showing that hope and effective treatment are within reach for millions.